Introduction
Nasopharyngeal carcinoma (NPC) has the highest incidence in Southern China and is one of the most common types of cancer in Southeast Asia (1, 2) . The possible etiological factors identified for NPC are genetic susceptibility, Epstein-Barr virus (EBV) infection and environmental risk factors. Although plasma EBV DNA quantification has been recommended as an independent biomarker for the prediction of survival (3, 4) , currently the prediction of prognosis for patients with NPC mainly depends on clinical staging. However, NPC patients with the same clinical stage often present different clinical outcomes, suggesting that the clinical staging is insufficient for accurate prediction of the prognosis of NPC.
NPC is more radiosensitive than other malignant tumors arising in the head and neck, making radiotherapy an important treatment modality for non-disseminated NPC. Although NPC is usually curable by radiotherapy, there are incidents of local failure and metastases (5, 6) . According to the clinical and biological behavior of NPC patients following radiotherapy, we subdivided NPC into four types: Type I (no primary and regional recurrence and no distant metastasis), type II (primary or regional recurrence and no distant metastasis), type III (no primary and regional recurrence, and distant metastasis) and type IV (primary or regional recurrence, and distant metastasis) (7) . The identification of prognostic factors that are more accurately correlated with treatment outcome would help in determining which NPC patients may benefit from a higher radiation dose or should undergo combined treatment with more aggressive chemotherapy. A number of candidate biological markers, such as p53, EGFR and Bcl-2 genes, have been reported. However, none of these markers have been established as a marker in decision-making for the treatment of NPC. Therefore, establishment of a biological marker that may determine prognosis and response to a particular treatment is essential in improving prognosis and developing individualized strategies, thus enhancing treatment outcome.
Aurora-A kinase (Aur-A), a member of the serine/threonine kinase family, is required for centrosome maturation and separation, mitotic commitment, chromosome alignment and possibly cytokinesis (8, 9) . Aur-A is located on chromosome 20q13.2, which is frequently amplified in epithelial cancers (10, 11) , suggesting the possible link of its dysregulation to carcinogenesis. Aur-A has been indicated as an oncogene since the ectopic overexpression of Aur-A in NIH3T3 and Aurora-A is an efficient marker for predicting poor prognosis in human nasopharyngeal carcinoma with aggressive local invasion:
208 cases with a 10-year follow-up from a single institution Rat-1 has been shown to induce cell transformation that generates tumors when implanted in nude mice (11) (12) (13) . In previous clinical studies, the Aur-A gene was found to be amplified or upregulated in various types of cancer characterized by chromosome instability (CIN), which is in agreement with the previous experimental results suggesting that Aur-A abnormalities are involved in carcinogenesis (14) (15) (16) (17) (18) . While a positive correlation of Aur-A abnormalities with aggressive tumor behavior and poor prognosis has been reported in recent studies with clinical tissues of certain cancers (14, 16, (19) (20) (21) , a poor correlation has also been reported for other types of cancer, indicating a possible dependence of the correlation on specific types of cancer (22) (23) (24) (25) . Previous studies indicated that Aur-A downregulation was capable of inducing cell death, reducing migration and enhancing radiosensitivity in human NPC. The epithelial-mesenchymal transition (EMT) is an important process that mediates cancer invasion and metastasis, and links to radioresistance (26, 27) . Additionally, Aur-A inhibition attenuated EMT (28) . Since the correlation between Aur-A status and disease progression has not been fully investigated in NPC, the present study was conducted to assess the expression of Aur-A in NPC and its correlation to the clinicopathological parameters, overall survival and diseasefree survival in 208 NPC patients.
Materials and methods
Tissue samples. This study was conducted on a total of 208 paraffin-embedded NPC samples obtained from patients who were histologically and clinically diagnosed at the Sun Yat-Sen University Cancer Center, China, between 1994 and 1999. Patient consent and approval from the Institute Research Ethics Committee was obtained prior to the use of these clinical materials for research purposes. The clinical characteristics of the patients are shown in Table I . There were 156 males and 52 females, with a median age of 48.1 years (range, .
The routine staging workup included a detailed clinical examination of the head and neck, fiberoptic nasopharyngoscopy, computed tomography (CT) imaging of the entire neck from the base of the skull, chest radiography, abdominal sonography, a complete blood count and a biochemical profile. The disease stages of all 208 patients were classified or reclassified according to the 1992 NPC staging system of China as mentioned in a previous study (29) . Follow-up information was obtained from all 208 patients. In total, 162 patients were treated with radiotherapy, six patients with chemotherapy, and 40 patients received both treatments. Radiotherapy was administered as 2 Gy daily fractions, 5 days per week, for a total intended dose of 70 Gy. Additional (boost) radiotherapy of 8-12 Gy was delivered for residual tumor and destructed skull base following a standard dose of 70 Gy. The neck received 50-70 Gy depending on the lymph node involvement, 50 Gy for node-negative necks and 60-70 Gy for node-positive necks. At 3 months following the completion of radiotherapy, the radiotherapy response was evaluated by clinical examination, CT scan and biopsy when required.
Immunohistochemical staining (IHC).
IHC staining was performed using Dako Envision system (Dako, Carpinteria, CA, USA) according to the manufacturer's instructions. Briefly, paraffin sections (4 µm) were baked for 1 h at 65˚C. The sections were deparaffinized in xylenes and rehydrated with graded ethanol to distilled water. The sections were submerged into EDTA antigenic retrieval buffer (pH 8.0) and microwaved for antigenic retrieval. After being treated with 0.3% H 2 O 2 for 15 min to block the endogenous peroxidase, the sections were treated with normal goat serum for 30 min to reduce the non-specific binding, and then rabbit polyclonal anti-Aur-A antibody (1:300; Upstate Biotechnology, Charlottesville, VA, USA) was incubated with the sections overnight at 4˚C. After washing, the sections were incubated with horseradish peroxidase (HRP) at 4˚C for 30 min. Diaminobenzidine (DAB) was used for the color reaction. For the negative controls, the antibody was replaced with normal goat serum.
Evaluation of staining. The immunohistochemically stained tissue sections were scored separately by two pathologists blinded to the clinical parameters. For Aur-A assessment, the entire tissue section was scanned to assign the scores. The staining intensity was scored as 0 (negative), 1 (weak), 2 (medium) or 3 (strong). The extent of staining was scored as 0 (0%), 1 (1-25%), 2 (26-50%), 3 (51-75%) and 4 (76-100%), according to the percentages of the positive staining areas in relation to the whole carcinoma area, or entire section for the normal samples. The sum of the intensity and extent score was used as the final staining scores (0 to 7) for Aur-A. This relatively simple, reproducible scoring method that yields highly concordant results between independent evaluators has been used in previous studies (30, 31 ). An optimal cut-off value was selected on the basis of a measure of heterogeneity with the log-rank test with respect to overall survival. For the purpose of statistical evaluation, tumors having a final staining score of ≤3 were classified as tumors with a low expression and those with a score of >3 were classified as tumors with a high expression of Aur-A antigen. (34, 35) . Our study revealed that Aur-A localized in the nucleus and cytoplasm in NPC tissues and localized only in the nucleus in normal nasopharyngeal columnar and squamous epithelia (Fig. 1) . Aur-A was highly expressed in 132 (63.5%) of the 208 NPC tissues. The Aur-A expression level was much higher in the tumor cells compared with the adjacent normal epithelial cells, indicating an increase of Aur-A in the tumor cells (Fig. 1) . Aur-A expression is associated with NPC T staging. Table II shows the association between Aur-A expression and the clinicopathological parameters. No significant correlation was found between Aur-A expression and age, gender, histological classification, N classification, distant metastasis or tumor relapse. However, Aur-A expression was significantly correlated with T classification (P= 0.012) and skull base invasion (P= 0.003). Moreover, Aur-A expression in late-stage NPCs was significantly higher than that in early-stage NPCs (P=0.003).
Inverse correlation of Aur-A overexpression with patient survival. In the entire cohort, the overall survival rate of the patients with a high Aur-A expression was significantly lower when compared with that of the low Aur-A expression group (P= 0.022, log-rank test; Fig. 2A ). The disease-free survival rate of the patients with a high Aur-A expression was also significantly lower (P=0.017, log-rank test; Fig. 2B (Table III) .
Lack of correlation of Aur-A with metastasis.
When NPC patients were classified into N 3 (supraclavicular lymph node, diameter >7 cm or fixed or skin infiltration) or M 1 (presence of distant metastasis), the tumors were considered to have a high metastatic potential. In N 3 or M 1 patients, Aur-A expression had no correlation with clinical outcome (n=40; log-rank, P=0.85) and further analysis demonstrated that Aur-A expression had no correlation with lymphatic metastasis and distant metastasis.
Close correlation of Aur-A expression with T 4 subgroup NPC
patients. The patients were divided into different subgroups according to N classification. Notably, in the N 0 (no enlarged lymph node) subgroup, we found that the patients with a high Aur-A expression had a significantly shorter survival time than those with a low Aur-A expression (n=128; log-rank, P=0.007; Fig. 2C ). However, in the N 1 -N 3 subgroups, there were no statistically significant differences between patients with low or high levels of Aur-A expression (n=80; log-rank, P=0.846). The N 0 subgroup was divided according to T classification and distant metastasis, and we found that the overall survival rate of patients with a high Aur-A expression was lower than that of those with a low Aur-A expression in the T 4 N 0 M 0 subgroup (n=30; P=0.042; Fig. 2D ). A trend towards shorter overall survival time of patients with a high Aur-A expression was revealed in the T 1-2 N 0 M 0 subgroup, but there was no statistically significant difference (n=61; log-rank, P=0.176). Aur-A was capable of predicting the clinical outcome of patients in the T 4 N 0 M 0 subgroup. Thus, we aimed to verify the correlation between Aur-A expression and the clinical outcome of T 4 patients. We divided all cases into T 1-2 , T 3 and T 4 subgroups. As expected, in the T 4 subgroups, a high Aur-A expression had a poor clinical outcome (n=35; log-rank, P=0.032; Fig. 2E ), whereas Aur-A expression had no correlation to clinical outcome in either T 1-2 or T 3 subgroups (P=0.415 and P=0.498). Thus, regardless of N or M status, a high Aur-A expression indicated poor prognosis in T 4 patients.
Correlation of Aur-A expression with radiosensitivity.
Radiotherapy is the major treatment modality for NPC. According to our radiotherapy-related definitions for NPC (NPC patients received five-year follow-up after radical radiotherapy alone), no primary and regional recurrence was defined as radiosensitive, and primary or regional recurrence was defined as radioresistant (7) . The disease-free survival (no recurrence and no metastasis) rate of the patients with a high Aur-A expression was significantly lower than a low Aur-A expression (P= 0.017, Fig. 2B ). Additionally, investigators found that Aur-A downregulation enhanced radiosensitivity in Table II . Correlation between the clinicopathologic characteristics and expression of the Aurora-A protein. human NPC in vitro (36) . Taken together, it indicated that a high Aur-A expression is capable of predicting radioresistance. NPC patients with local relapse accompanied by skull base invasion have been reported to be less sensitive to radiation therapy and have a poorer clinical outcome than other patients (37) . In this study, there were 7 recurrent NPC patients with skull base invasion. All 7 of these patients exhibited a high expression of Aur-A and 5 of the 7 patients (71.4%) succumbed to NPC, indicating a possible correlation of a high Aur-A expression with radiosensitivity.
Aurora-A (%) --------------------------------------------
Previous studies have shown that primary tumor volume had a close correlation with survival rates and the treatment outcomes of patients with NPC (3, 18, 38) . Larger tumor volume may require more aggressive treatment, suggesting that T 4 patients were not sensitive to radiation therapy. In the present study, we found that Aur-A expression served as an indicator for clinical outcome in patients of the T 4 subgroup. Therefore, radiotherapy combined with an Aur-A inhibitor may be of benefit for T 4 patients.
Discussion
In this study, we have shown that Aur-A is overexpressed in NPCs compared with their normal adjacent epithelia. Our results showed that an increased expression of Aur-A was significantly associated with tumor aggressive variables, including T classification, skull base invasion and clinical stage. These findings are consistent with a previous report that Aur-A is overexpressed in laryngeal squamous cell carcinoma (LSCC) and associated with advanced tumor stage (16) . Additionally, a significant correlation was found between a high Aur-A expression with shortened overall and disease-free survival time in NPC patients, indicating that Aur-A may be an independent prognostic factor. Consistent with our findings, certain reports have also suggested that Aur-A is a potential prognostic biomarker in breast cancer (39) , bladder cancer (40), hepatocellular carcinoma (19) , medulloblastoma (41), esophageal squamous cell carcinoma (35) and head and neck squamous cell carcinoma (42) . However, there is controversy regarding the use of Aur-A expression as a progressive marker in glioma (23), pancreatic carcinoma (22) , ovarian cancer (24) or as a prognostic marker in breast cancer (25) . We speculated that the differences in the reported clinical studies may be attributed to the variability in population size, tumor characteristics, antibodies and IHC staining protocol. Our findings were obtained by analysis of a relatively large number of cases in a single institution, and thus, should be of considerable interest.
The precise mechanism by which the upregulation of Aur-A affects the process of carcinogenesis and tumor progression has yet to be clearly elucidated. A number of studies have reported that deregulation of the Aur-A function impairs genomic integrity and thus contributes to tumorigenesis by its association or interaction with its effectors or activators such as p53, TPX2, BRCA1, TACC and RASSF1A (43, 44) . Aur-A may phosphorylate p53 at Ser215 or Ser315 and result in inactivation of the p53 transcriptional activity or facilitation of MDM2-mediated degradation (45, 46) . Aur-A also induces telomerase activity by upregulation of c-Myc (47) . Phosphorylated Aur-A may be correlated with tumor cell proliferation, inhibition of apoptosis and resistance to chemotherapeutic drugs (48) . Disturbance of these factors by abnormal Aur-A expression or activity may affect tumorigenesis and tumor progression. Notably, results of previous studies revealed that a high Aur-A expression is associated with radioresistance and EMT in human NPC (28, 36) .
A number of useful biological markers have already been identified to predict prognosis and aid in clinical decisionmaking in NPC in the following regards: high Met protein and syndecan-1 expression levels correlate with poorer survival in late-stage NPC (49, 50) ; cyclin D1 predicts NPC recurrence and tumor response to radiation therapy (51); quantification of plasma EBV DNA correlates with the response to treatment and the likelihood of relapse and survival (52) ; and other biomarkers such as Bmi-1, CENP-H and cathepsin D could predict the poor clinical outcome of NPC patients (53) (54) (55) . Although these biological markers are likely to improve the validity of molecular classification in the future, none are capable of predicting the T 4 subgroup and no small molecule inhibitor has been developed thus far.
The present data have demonstrated a statistically significant correlation between Aur-A and T classification of NPC. Particularly, in the T 4 subgroup, and even in the T 4 N 0 M 0 subgroup, patients with a high Aur-A expression had a poorer prognosis than those with a low Aur-A expression. Thus, we speculated that T 4 subgroup patients would benefit from the chemical inhibition of Aurora kinase to improve treatment outcome. Recently, Aurora kinase inhibitors have been developed and VX-680 has shown promising results in in vivo studies (44) . The potential of sensitizing NPC cells to radiotherapy by inhibiting Aur-A activity provided the feasibility of combinational treatment for the T 4 NPC patient subgroup.
The correlation analysis in the present study does not appear to indicate a significant correlation of Aur-A with lymphatic or distant metastasis, in contrast to a previous report on head and neck squamous cell carcinoma (HNSCC) showing that the upregulation of Aur-A was significantly associated with tumor distant metastasis (42) . Furthermore, the present study has shown that in N 3 or M 1 subgroup patients, Aur-A expression does not appear to have a correlation with clinical outcome, indicating that Aur-A activity is not linked to metastasis and that Aur-A may not be involved in the metastatic process, at least in NPC. The difference of Aur-A expression in NPC and HNSCC may be attributed to the unique features of NPC. NPC is distinctive in head and neck carcinoma for its marked geographical variation shown in incidence, its close association with EBV, its highly metastatic nature and its unique clinical development features (56, 57) .
Taken together, results of the present study have demonstrated that the level of Aur-A expression was highly elevated in NPC, inversely correlated with survival and directly correlated with the malignant status of NPC. The present findings suggests that Aur-A is a biological marker that may be used to identify a subgroup of patients with poor prognosis for new treatment approaches. An Aurora kinase inhibitor that sensitizes NPC cells to radiotherapy would offer an opportunity for future target-guided combinational therapy. 
